Abstract
Atypical femur fractures are rare but a growing concern, as they are more common in patients who use bisphosphonates. The best radiology-based studies have had access to only short-term exposure data, while the studies using prescription databases with substantial long-term data did not have access to radiology reports. The interests of the patients are probably best served by reserving long-term bisphosphonate treatment for patients who are at the highest risk of osteoporotic fractures and considering drug holidays after 5 years in patients at low risk. Recent studies have further strengthened the case for active medical or surgical therapy in patients with incomplete fractures, but patient numbers are small, and randomized controlled trials may not be forthcoming in the immediate future. The recommendations made to establish an international database for such fractures have not yet been followed, and more epidemiologic and pathophysiologic research is needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
• Shane, E., Burr, D., Ebeling, P. et al.: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25, 2267–2294. This is an international scientific report with a proposed case definition; a review of publications available at the time; and initial recommendations for prevention, treatment, and research.
Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011;22:373–90.
•• Schilcher, J., Michaelsson, K. and Aspenberg, P.: Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364, 1728–1737. This was a large, register-based study with x-ray adjudication of all ST and shaft fractures in postmenopausal Swedish women in the year 2008, coupled to information from the Swedish prescription database dating back to July 2005.
Giusti A, Hamdy NAT, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48:966–71.
Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305:783–9.
Abrahamsen, B.: Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. Evid Based Med 2011 (online).
Vestergaard P, Schwartz F, Rejnmark L, et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011;22:993–1001.
Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010;95:5258–65.
Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011;26:993–1001.
Puhaindran ME, Farooki A, Steensma MR, et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011;93:1235–42.
Tan SC, Koh SBJ, Goh SK, et al. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int. 2011;22:2211–2.
Cheung A, Bogoch E, Khan A, et al. Exploring differences in bone density and structure between patients on bisphosphonates with atypical femur fractures and other populations. Osteoporos Int. 2011;22 suppl 1:S351.
Yates CJ, Bartlett MJ, Ebeling PR. An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature. J Bone Miner Res. 2011;26:1377–9.
Brennan O, Kennedy OD, Lee TC, et al. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res. 2011;29:419–24.
•• Koh, J.S.B., Goh, S.K., Png, M.A. et al.: Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 2011;52, 77–80. This is a good radiological review of 48 patients with atypical femoral fractures, and comparison of fracture site with established FS loading characteristics.
Unnanuntana, A., Ashfaq, K., Ton, QV. et al.: The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res 2011.
• Allen, M.R. and Burr, D.B.: Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don’t know. Bone 2011;49, 56–65. This is a review of bisphosphonates, highlighting current knowledge and areas of uncertainty around the role that they play in modulating bone turnover.
Bauer DC. Bisphosphonate use and atypical femoral fractures: getting down to brass tacks. J Clin Endocrinol Metab. 2010;95:5207–9.
Eastell R, Walsh J, Watts N, et al. Bisphosphonates for postmenopausal osteoporosis. Bone. 2011;49:82–8.
• Banffy, M.B., Vrahas, M.S., Ready, J.E. et al.: Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 2011;469, 2028–2034. This is a case series describing clinical recovery and surgical treatment in 34 patients who developed femoral fractures after bisphosphonate therapy, showing that 5 of 6 fractures that were initially treated nonsurgically progressed to complete fractures.
Ha Y, Cho M, Park K, et al. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010;468:3393–8.
Weil YA, Rivkin G, Safran O, et al. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma. 2011;71:186–90.
Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96:1627–32.
Carvalho NNC, Voss LA, Almeida MOP, et al. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011;96:2675–80.
Disclosure
Dr. Abrahamsen has served on advisory boards for Amgen and Nycomed; has served as a consultant for Novartis, Merck & Co., and Amgen; has received grant support from Novartis and Amgen; has served on speakers’ bureaus for Eli Lilly and Company, Nycomed, and Merck & Co.; and has had travel/accommodations expenses covered/reimbursed by Nycomed.
Dr. Clark received a local FSF grant to produce pilot data.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abrahamsen, B., Clark, E.M. Disentangling the Emerging Evidence around Atypical Fractures. Curr Rheumatol Rep 14, 212–216 (2012). https://doi.org/10.1007/s11926-012-0241-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-012-0241-y